scroll
UP

A/Prof Louise Purton

Research Unit

Stem cell regulation

Information

Associate Director, SVI
Head, Stem Cell Regulation Laboratory
Associate Professor, Dept of Medicine SVH, The University of Melbourne

email: lpurton@svi.edu.au

Professional Experience

1990         BSc (Hons) The University of Melbourne, Australia
1995         PhD, The University of Melbourne, Australia
1995-00    Post-doctoral researcher, Fred Hutchinson Cancer Research Center
2000-04    Senior Research Officer, Peter MacCallum Cancer Centre, Melbourne
2004-05    Associate, Peter MacCallum Cancer Centre, Melbourne
2004-07    Visiting scientist, Massachusetts General Hospital Center, Boston, USA
2004-07    Assistant in Biology, Massachusetts General Hospital, Boston, USA
2004-07    Instructor, Department of Medicine, Harvard University, Boston, USA

Achievements

1993-94      Postgraduate Bursary, The British Council
1999-02      Special Fellowship, The Leukemia and Lymphoma Society of America
2008           NHMRC Career Development Award, Level 2
2009           Member, Faculty 1000, Non-hematopoietic stem cells section
2010 -13     Director, ISEH Society for Hematology and Stem Cells
2011-15      NHMRC Senior Research Fellowship
2014 -         Member, Editorial Board, PLoS One
2015 -         Member, Standing Research Subcommittee, Cancer Council Victoria
2016 -         Member, Editorial Board, Scientific Reports
2017 -         Member, ASH Scientific Committee on Stem Cells and Regenerative Medicine
2017 -         Member, Editorial Board, Experimental Hematology

Research Interests

The research in my lab primarily focuses on processes involved in blood cell production (haematopoiesis). All blood cells are formed from haematopoietic stem cells (HSCs), which are capable of either self-renewing (to make more HSCs) or differentiating into mature blood cell types- each HSC makes hundreds of thousands of blood cells. HSCs are finely regulated, and problems in the regulation of HSCs can lead to haematopoietic diseases (such as leukaemia) or blood cell exhaustion. Research in my laboratory is focused on understanding how HSCs are regulated, and determining the roles of the bone marrow microenvironment (where blood cells are made) in regulating haemopoietic diseases, including leukaemia. Of major interest are the roles of the receptors for vitamin A (retinoic acid receptors, RARs) in these processes. Our approaches include the use of different mouse knockout models, stem and progenitor cell assays including bone marrow transplantation studies and ex vivo culture methods, mCT analysis of bone marrow microenvironment cells, gene transduction, FACS-based methods for sorting and analysis, analysis of gene expression by quantitative real-time PCR and microarrays.

Selected Publications

  1. Purton LE, Bernstein ID, Collins SJ. All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin- c-kit+ Sca-1+) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Blood 1999; 94:483-495.
  2. Purton LE, Bernstein ID, Collins SJ. All-trans retinoic acid enhances the maintenance of long-term repopulating hematopoietic stem cells. Blood 2000; 95:470-477.
  3. Walkley CR, Fero ML, Chien W-M, Purton LE*, McArthur GA*. Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol 2005; 7:172-178. *Purton and McArthur are equal senior authors.
  4. Purton LE, Dworkin S, Olsen GH, Walkley CR, Fabb SA, Collins SJ, Chambon P. RARg is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med 2006; 203:1283-1293.
  5. Walkley CR*, Olsen GH*, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor g deficiency. Cell 2007; 129:1097-1110. *Walkley and Olsen are equal first authors.
  6. Askmyr M, Sims NA, Martin TJ, Purton LE. What is the true nature of the osteoblastic hematopoietic stem cell niche? (Invited Review) Trends in Endocrinology and Metabolism. 2009; 20:303-309.
  7. Chee LC, Hendy J, Purton LE, McArthur GA. ATRA and the specific RARa agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells. Leukemia 2013; 27:1369-1380.
  8. Joseph C, Quach JM, Walkley CR, Lane SW, Lo Celso C, Purton LE. Deciphering hematopoietic stem cells in their niches: a critical appraisal of genetic models, lineage tracing, and imaging strategies. Cell Stem Cell 2013; 13:520-533.
  9. Quach JM, Askymr M, Jovic T, Baker EK, Walsh NC, Harrison SJ, Neeson P, Ritchie D, Ebeling PR, Purton LE. Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. JBMR 2015; 30:886-897.
  10. Joseph C, Nota C, Fletcher JL, Maluenda AC, Green AC, Purton LE. Retinoic acid receptor γ regulates B and T lymphopoiesis via nestin-expressing cells in the bone marrow and thymic microenvironments. The Journal of Immunology 2016; 196:2132-2144.
  11. Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK, Rothery S, Ruivo N, Foster K, Waibel M, Johnstone RW, Harrison SJ, Westerman DA, Quach H, Gribben J, Robinson MD§, Purton LE§, Bonnet D§, Lo Celso C. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 2016; 538:518-522. § Robinson, Purton and Bonnet are co-second last authors.
  12. Duarte D, Hawkins ED, Akinduro O, Ang H, De Filippo K, Kong IY, Haltalli M, Ruivo N, Straszkowski L, Vervoort SJ, McLean C, Weber TS, Khorshed R, Pirillo C, Wei A, Ramasamy SK, Kusumbe AP, Duffy K, Adams RH, Purton LE, Carlin LM, Lo Celso C. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell 2018; 22:64-77.